Private EquityScreenerRefer

MARKET INSIGHTS

  • EventsNEWPrivate market milestones
  • NewsPrecize daily pulse
  • BlogsIn-depth articles and opinions

GUIDES

Explore Now
  • Unlisted SharesStep-by-step · KYC
  • BuyingStep-by-step · KYC
  • SellingExit in 24 - 48 hours
  • Pre-IPOReturns · risks · case studies
  • Tax GuideBudget 2026 changes
  1. Home
  2. Unlisted share news
  3. PharmEasy Valuation Slashed 92% From Peak In Latest Janus Henderson Fil…

PharmEasy Valuation Slashed 92% From Peak In Latest Janus Henderson Filing

3 Sept 2024

Add as preferred source
Key Takeaways

PharmEasy's valuation slashed 92% to $460 million due to widening losses, modest revenue growth, and rising competition.

PharmEasy's valuation slashed 92% to $460 million due to widening losses, modest revenue growth, and rising competition.

pharmeasy unlisted shares

API Holdings (Pharmeasy)

-8.09%

Expert Analysis

PharmEasy Valuation Plummets 92% in Latest Janus Henderson Filing.

Expert Analysis:

  • Valuation Reduction: API Holdings Pvt. (PharmEasy) valuation was cut by 92% to $460 million by Janus Henderson.

  • Valuation Drop: At the end of 2021, Janus Henderson valued PharmEasy at approximately $5.6 billion In the latest SEC filing, the value of these shares has dropped by 92%, reducing PharmEasy's worth to around $460 million.

  • Earlier Valuation Slash: The struggling e-pharmacy experienced a 90% reduction from its peak valuation in April this year when it raised Rs 1,800 crore, led by Ranjan Pai's Manipal Education and Medical Group and existing investors.

  • Revenue Growth: FY23 revenue increased 16% to Rs 6,644 crore, up from Rs 5,728.8 crore in FY22.

  • Losses Widened: The Company Losses widened to Rs 5,211.7 crore from Rs 3,992.4 crore in FY22. It faces increased competition from rivals like Tata 1mg, Medlife, Flipkart Health+, and Reliance-backed Netmeds.

Publisher:NDTV profit